Adia Nutrition Inc. Celebrates Grand Opening of Adia Med of San Antonio, First Licensed Clinic, Led by Michele DeLeon MDJuly 14, 2025 9:28 AM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - July 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine, proudly announces the grand opening of Adia Med of San Antonio, its first licensed clinic under a strategic license agreement, located at 18707 Hardy Oak Blvd, Suite 500, San Antonio, Te ...

Core Insights - Creative Medical Technology Holdings, Inc. has received a Notice of Allowance for a U.S. patent related to treating heart failure and post-infarct pathological remodeling using its ImmCelz product, with the patent expected to be effective until at least 2040 [1][2]. Group 1: Patent and Product Details - The patent covers treatment for patients at risk of or already experiencing heart failure, utilizing the proprietary ImmCelz product [2]. - The total addressable market for heart failure treatment in the U.S. exceeds five million patients, with an additional six million patients suffering from chronic chest pain who may benefit from the ImmCelz product [2]. - ImmCelz is administered through an ultra-minimally invasive outpatient procedure [2]. Group 2: Company Strategy and Technology - The CEO of Creative Medical emphasized that the Notice of Allowance enhances the company's intellectual property portfolio and reflects the potential of its cell-based technology for developing therapies across various indications [3]. - The ImmCelz platform involves reprogramming a patient's immune cells outside the body with optimized cell-free factors before re-injecting them, which is believed to enhance their regenerative properties [4]. - Creative Medical is focused on pioneering regenerative medicine solutions across multiple indications, including pain management, neurology, and urology [5].

SAN DIEGO, July 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit.  Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with vi ...

Core Insights - Fifty1 AI Labs, LLC has successfully completed the REVIVE Adaptive Platform Trial, the largest Long COVID study to date, addressing a health crisis affecting approximately 400 million people globally and 15% of COVID-19 survivors, with an economic burden exceeding USD 1 trillion annually [1][2] - The trial demonstrates a clear treatment benefit for Long COVID, aligning with Fifty 1 Labs, Inc.'s vision to revolutionize healthcare through AI-driven drug repurposing and functional medicine, targeting the $5.68 trillion biotech market [2][3] - The company aims to achieve a $50 million valuation and lead the $320.6 billion functional medicine market, enhancing investor confidence and positioning for uplisting to OTCQB by Q1 2026 and NASDAQ in the coming years [2][7] Company Achievements - The REVIVE Trial enrolled over 600 participants, achieving the fastest recruitment for a study of its kind, showcasing operational excellence and strategic partnerships with leading institutions [3][4] - Fifty1 AI Labs' proprietary AI platform, supported by a $1 million R&D investment, optimizes drug candidate selection and accelerates clinical research efficiency, setting a new standard in the industry [4][5] - The findings from the REVIVE Trial are expected to establish a foundation for polypharmacy-based treatment regimens, unlocking significant opportunities for intellectual property development and potential annual revenue in the billions [5][6] Strategic Initiatives - The company is pursuing regulatory pathways to bring novel therapies to market and establishing R&D hubs in Vancouver, alongside strategic partnerships with pharmaceutical leaders [7] - Upcoming initiatives include the launch of a minimum viable product website by July 24, 2025, and a fully interactive website by July 31, 2025, aimed at enhancing investor engagement [7] - A virtual shareholder teleconference is scheduled for July 28, 2025, to provide insights into the company's transformative vision and progress toward uplisting [7]

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top ...

Fountain Life operates four flagship longevity centers, including two in Florida, where a new state law effective July 1, 2025, authorizes licensed physicians to administer stem cell therapies to members with conditions in orthopedics, wound care, and pain management. FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, announced today that it entered into ...

Ready-made stem cell therapies for pets could be coming | TechCrunch https://t.co/ukOEqmlBkX ...

Clinical Pipeline and Regulatory Milestones - The company has 3 late-stage clinical programs in pivotal/Phase 3 trials for prevalent non-inherited indications[4,7,30,36,42,90] - Potential global filings are anticipated in 2025, 2026, and 2027[7,30,36,42,90] - The company has a deep pre-IND pipeline targeting conditions like ALS, MC4R obesity, and metabolic disease[7,8,32,38,45,93] Manufacturing and Technology - The company operates 2 GMP facilities at commercial scale[5,9,33,39,46,94] - Proprietary vectorization technology increases potency by 2-10x from the same promoter[5,9,34,40,47,95] - AI-driven improvements are based on over 20 vectors and more than 50 GMP runs[5,9,33,39,46,94] Partnerships and Financials - MeiraGTx will receive up to $415 million from Janssen through an asset purchase agreement[11] - Sanofi made a $30 million strategic investment through the sale of 4 million ordinary shares at $7.50 per share[11] AAV-AQP1 for Radiation Induced Xerostomia - There are 170,000 Grade 2/3 RIX patients in the US[13] - There are 15,000 new cases of grade 2/3 RIX annually in the US[13] AAV-GAD for Parkinson's Disease - There are 10 million Parkinson's patients worldwide[18,28] - The estimated economic burden of Parkinson's Disease in the US is $52 billion[19]

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of 3D Systems Corporation (NYSE: DDD). Shareholders who purchased shares of DDD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/3d-systems-corporation-loss-submission-form/?id=155073&from=3 CLASS PERIOD: Aug ...

"2025沪港创新项目评选"活动以"沪港联动科创共融"为主题，聚焦人工智能、生物医药等战略性新兴产 业。活动自5月启动以来，已收到多个团队报名参赛。辅导营上，上海市香港商会副会长、创新项目评 选负责人黎庆文全面介绍评选机制。上海市香港商会理事会、创新小组成员王文耀解读评选标准，从创 造性、可行性、团队能力等维度，为项目提供优化方案。 7月2日， 2025沪港创新项目评选辅导营在上海成功举办。香港贸发局供图 中新网上海7月2日电 (记者 李佳佳)由上海市香港商会主办的"2025沪港创新项目评选"活动正在火热报 名中。为帮助参赛者深度了解评选规则、优化项目方案，上海市香港商会于2日邀请人工智能、生物医 药等领域专家、投资人分享创新实践，采用"线下分享+线上直播"模式，搭建沪港科创资源交流对接平 台。 据了解，本次评选面向初创公司、大学生和创意个人/团体，采用"双赛道"模式，分为初创组(公司或团 队成员在10人以下，融资轮次为一次或以下)和成长组(公司人数不超过50人，融资轮次为三次或以下)， 通过"全周期培育"体系提供从初审、辅导营到路演和资本对接的全流程支持，并依托"跨境资源赋能"联 动沪港四大园区(上海外高桥 ...